Enoxrin

Enoxaparin Na

4,000 anti-Xa IU/0.4 mL: Prophylactic treatment of venous thromboembolic disease in moderate or high risk surgery. Prophylactic treatment of DVT in bedridden patient due to acute medical condition eg, heart failure (NYHA class III or IV), acute resp failure, acute infection or acute rheumatic disorder associated w/ at least 1 other VTE risk factor. 6,000 anti-Xa IU/0.6 mL: Treatment of acute ST-segment elevation MI as an adjunct to thrombolytic & in combination w/ anti-aggregation treatment, including patients to be managed medically or w/ subsequent percutaneous coronary intervention (PCI).

SC Prophylactic treatment of venous thromboembolic disease in surgery Patient w/ moderate thrombogenic risk 2,000 anti-Xa IU (0.2 mL) daily. Patient w/ high thrombogenic risk (eg, hip & knee surgery, cancer surgery) 4,000 anti-Xa IU (0.4 mL) once daily. Prophylactic treatment of DVT in bedridden patient due to acute medical condition 4,000 anti-Xa IU/0.4 mL once daily for 6-14 days. Prevention of clotting in extracorporeal circulation/hemodialysis Initially 100 anti-Xa IU/kg into arterial line of dialysis circuit at beginning of session as single intravascular bolus inj for a ≤4-hr session, an additional dose of 50-100 anti-Xa IU/kg may be injected if fibrin rings are found. Hemodialysis patient w/ high risk hemorrhage (especially dialysis before or after surgery) or w/ active hemorrhage 50 anti-Xa IU/kg (double vascular access) or 75 anti-Xa IU/kg (single vascular access). DVT w/ or w/o pulmonary embolism, w/o signs of clinical severity 2 inj daily at 12-hr intervals w/ a dose of 100 anti-Xa IU/kg for patient 40-100 kg for 10 days. Oral anticoagulant therapy should be quickly initiated. Unstable angina/non-Q-wave MI 100 anti-Xa IU/kg SC twice daily at 12-hr intervals w/ aspirin 75-325 mg orally, following min loading dose of 160 mg for 2-8 days until clinically stable. Acute ST-segment elevation MI & in combination w/ thrombolytic agent in patient eligible or not for subsequent coronary angioplasty Initially 3,000 anti-Xa IU IV bolus inj followed by 100 anti-Xa IU/kg SC w/in 15 min then every 12 hr. Max: 10,000 anti-Xa IU for the 1st 2 SC doses. 1st dose should be administered between 15 min before & 30 min after start of thrombolytic treatment. Max duration: 8 days. Concomitant therapy w/ aspirin: 75-325 mg daily for at least 30 days. Patient treated by coronary angioplasty 30 anti-Xa IU/kg IV bolus if last SC inj was performed >8 hr before balloon inflation. Elderly ≥75 yr 75 anti-Xa IU/kg SC every 12 hr. Max dose: 7,500 anti-Xa IU for the 1st 2 SC inj.

Hypersensitivity to enoxaparin, heparin or heparin derivatives or other LMWH. History of enoxaparin or heparin-induced thrombocytopenia. Bleeding or tendency to bleed related to impaired hemostasis; organic lesion w/ tendency to bleed; clinically significant active bleeding. Not recommended in cases of haemorrhage stroke, uncontrolled arterial HTN, acute infectious endocarditis. Severe renal failure (CrCl <30 mL/min). 6,000 anti-XA IU/0.6 mL: Intracerebral bleeding. Not recommended in cases of acute extensive ischemic stroke w/ or w/o impaired consciousness, mild to moderate renal failure.

Spinal/epidural anesth. Risk of hemorrhage in elderly, patient w/ renal failure, wt <40 kg, treatment duration of >10 days, non-compliance w/ therapeutic recommendations & co-administration w/ drugs increasing risk of hemorrhage. Risk of heparin-induced thrombocytopenia (HIT). Patient w/ mechanical prosthetic heart valves. Obese patients (BMI >30 kg/m²). Pregnancy. Childn.

Impaired immune system (cutaneous or systemic allergy); headache; hemorrhage; thrombocytopenia; increased thrombocytosis (asymptomatic & reversible); hemorrhage anemia; hypereosinophilia; vasculitis, skin necrosis, alopecia; hepatocellular or cholestatic disorders; osteoporosis (long-term use).

ASA (at analgesic, anti-pyretic & anti-inflammatory doses), NSAIDs (systemic use), dextran 40 (parenteral use), ticlopidine, corticosteroid (glucocorticoid), oral anticoagulant, platelet aggregation inhibitors (eg, abciximab, ASA at antiaggregant doses in cardiological & neurological indications, beraprost, clopidogrel, eptifibatide, iloprost, ticlopidine, tirofiban).

Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)

B01AB05 - enoxaparin ; Belongs to the class of heparin group. Used in the treatment of thrombosis.

G